Jefferies Maintains a 'Buy' on NuVasive (NUVA) as 2012 Guidance Looks Achievable
Tweet
Share
E-mailGet Alerts NUVA Hot Sheet
Price: $39.75 --0%
Rating Summary:
11 Buy, 21 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
11 Buy, 21 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Jefferies maintains a 'Buy' on NuVasive (NASDAQ: NUVA) price target cut from $30 to $20.
Jefferies analyst says, "NuVasive's 4Q showed continued share gains in the lumbar market and guidance for 2012 contemplates more of the same. The outlook for Biologics and International were tempered but NuVasive has set what appear to be achievable targets. With continued best-in-class performance in spine and with profitability an increasing focus, we maintain our rating."
"While share gains have moderated, the company still gained about 90bp in the U.S. and 60bp of worldwide share in 2011. We estimate NUVA finished 2011 at under 10% U.S. share and just 6% worldwide."
For an analyst ratings summary and ratings history on NuVasive click here. For more ratings news on NuVasive click here.
Shares of NuVasive closed at $15.46 yesterday.
Jefferies analyst says, "NuVasive's 4Q showed continued share gains in the lumbar market and guidance for 2012 contemplates more of the same. The outlook for Biologics and International were tempered but NuVasive has set what appear to be achievable targets. With continued best-in-class performance in spine and with profitability an increasing focus, we maintain our rating."
"While share gains have moderated, the company still gained about 90bp in the U.S. and 60bp of worldwide share in 2011. We estimate NUVA finished 2011 at under 10% U.S. share and just 6% worldwide."
For an analyst ratings summary and ratings history on NuVasive click here. For more ratings news on NuVasive click here.
Shares of NuVasive closed at $15.46 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Raymond James Starts Southern California Bancorp (BCAL) at Outperform
- NetEase.com (NTES) PT Lowered to $143 at Macquarie
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
